These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3838399)

  • 21. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation.
    Block HU; Förster W; Heinroth I
    Arzneimittelforschung; 1982; 32(3):189-94. PubMed ID: 6896278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molsidomine in ergometric tests (author's transl)].
    Röhl D; Lehmann KH
    Dtsch Med Wochenschr; 1980 Aug; 105(35):1216-9. PubMed ID: 6893580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of molsidomine and other NO-containing vasodilators on cyclic GMP formation.
    Böhme E; Grossman G; Spies C
    Eur Heart J; 1983 May; 4 Suppl C():19-24. PubMed ID: 6311553
    [No Abstract]   [Full Text] [Related]  

  • 24. Active and passive changes in coronary diameter after vasodilation with SIN-1, the active metabolite of molsidomine.
    Schulz W; Kober G; Bernauer R; Kaltenbach M
    Am Heart J; 1985 Mar; 109(3 Pt 2):694-9. PubMed ID: 3838406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemodynamic effects of molsidomine, isosorbide dinitrate, and nifedipine at rest and during exercise.
    Schartl M; Dougherty C; Rutsch W; Schmutzler H
    Am Heart J; 1985 Mar; 109(3 Pt 2):649-53. PubMed ID: 3838401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term clinical and hemodynamic results of molsidomine treatment in patients with refractory heart failure.
    Acar J; Kulas A; Escudier B
    Am Heart J; 1985 Mar; 109(3 Pt 2):685-7. PubMed ID: 3883737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of molsidomine on coronary artery thrombosis and myocardial ischemia in acute canine experiments.
    Fiedler VB
    Eur J Pharmacol; 1981 Jul; 73(1):85-9. PubMed ID: 6895623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of molsidomine and its active metabolite SIN-1 on fibrinolysis and platelet aggregation.
    Basista M; Grodzińska L; Swies J
    Thromb Haemost; 1985 Dec; 54(4):746-9. PubMed ID: 3911480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of molsidomine during the cold test in stable coronary insufficiency under beta-blocker treatment].
    Zygelman M; Neukirch F; Mérillon JP; Dahan M; Trouillet JL; Juliard JM; Pansard Y; Gourgon R
    Arch Mal Coeur Vaiss; 1984 Nov; 77(12):1383-9. PubMed ID: 6150693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The activity of molsidomine in experimental models of ischemic cardiac disease.
    Nitz RE; Martorana PA
    Am Heart J; 1985 Mar; 109(3 Pt 2):631-6. PubMed ID: 3919549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of molsidomine in plasma by high-performance liquid column chromatography.
    Dell D; Chamberlain J
    J Chromatogr; 1978 Nov; 146(3):465-73. PubMed ID: 757963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of molsidomine in the long-term treatment of exertional angina pectoris and chronic congestive heart failure.
    Rudolph W; Dirschinger J
    Am Heart J; 1985 Mar; 109(3 Pt 2):670-4. PubMed ID: 3883733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term treatment of patients with coronary heart disease using isosorbide dinitrate, nifedipine and molsidomine.
    Jansen W; Tauchert M; Osterspey A; Hombach V; Fuchs M; Hilger HH
    Z Kardiol; 1983; 72 Suppl 3():203-10. PubMed ID: 6689389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of the vasodilator molsidomin in the treatment of chronic cardiac insufficiency].
    Mareev VIu; Sazonova LN; Grigor'iants RA; Lobova NM; Irani RM
    Ter Arkh; 1983; 55(9):76-80. PubMed ID: 6688891
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetics of molsidomine and of its active metabolite, SIN-1 (or linsidomine), in the elderly.
    Spreux-Varoquaux O; Ulmer B; Cordonnier P; Forestier A; Pays M; Ducreuzet C; Advenier C
    Fundam Clin Pharmacol; 1991; 5(6):549-56. PubMed ID: 1955198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers.
    Wildgrube HJ; Ostrowski J; Chamberlain J; Gärtner W; Stockhausen H
    Arzneimittelforschung; 1986 Jul; 36(7):1129-33. PubMed ID: 3768083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and hemodynamic effects of the new dilator drug molsidomine.
    Malcolm AD
    Am Heart J; 1985 Mar; 109(3 Pt 2):674-7. PubMed ID: 3883734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molsidomine in the treatment of acute heart failure.
    Drajer S; Vazquez A; Cercós H; Torres H; Cohn JL; Romero N; Faerman G; Soifer S; Nijensohn CM
    Am Heart J; 1985 Mar; 109(3 Pt 2):712-5. PubMed ID: 3838409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of linsidomine (SIN 1) after single and multiple intravenous short infusions in patients with renal insufficiency.
    Sennesael J; Verbeelen D; Degré S; Unger P; Stolear JC; Ostrowski J; von Hattingberg HM; Gaertner W
    Int J Clin Pharmacol Ther Toxicol; 1993 Nov; 31(11):533-41. PubMed ID: 8294165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [We need molsidomine for complete prevention of ischemia. Interview with Prof. Rudolph on the therapy of coronary heart disease].
    Rudolph W
    Fortschr Med; 1986 Apr; 104(13):52. PubMed ID: 3754533
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.